MEDI-528, now recognized as enokizumumab, represents a novel treatment targeting the IGF1R, a vital protein implicated in several dermatological diseases . Early investigation results suggest significant efficacy for the management of substantial itchy skin, particularly in individuals who have not benefited from existing treatments . This antibody